Questions are being raised about the 12-16 week gap between two doses of Corona's vaccine Kovishield, while on the other hand the vaccine maker AstraZeneca has justified the gap of three months between Kovishield in India. The principal investigator of the AstraZeneca vaccine clinical trial said the level of protection provided by a single dose increases significantly in the second and third months after vaccination.
In an interview recently, Professor Andrew Pollard said that India and Britain have different circumstances and climates. Therefore the vaccination policy in the two countries cannot be compared. Pollard, director of the Oxford Vaccine Group, said the goal of a vaccination policy is to give the maximum number of people as soon as possible the minimum dose of the vaccine. The policy adopted in India is correct.
It is necessary to ensure the safety of as many people as possible
Pollard, professor of pediatric infection and immunity at the University of Oxford, UK, and director of the Oxford Vaccine Group, said AstraZeneca is not working on a single-dose vaccine. He said that in view of the lack of vaccines, it is better to ensure safety measures for as many people as possible and in India's vision, instead of providing a better level of protection to a small number of people, it is better to ensure the protection of maximum people. It is necessary.